GlobalData on MSN1d
Boehringer and partners commence gene therapy trial for cystic fibrosisBoehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...
Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, today ...
OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...
Mechelen, Belgium Monday, February 17, 2025, 16:00 Hrs [IST] ...
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.
Carrier Transicold has introduced the second generation of its fully electric Vector eCool trailer refrigeration unit (TRU), ...
The proof-of-concept study is one of the first to combine B and T cell analysis and potentially paves the way for tests that ...
IFLScience on MSN1d
Inhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical TrialsA new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...
Vector-borne zoonotic diseases, transmitted by pathogens via arthropods like mosquitoes, ticks, and fleas, comprise 17% of the global infectious disease ...
UNC Charlotte officially achieved Research 1, or R1, status this week, after doubling its research spending over the last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback